Identification of tobramycin impurities for quality control process monitoring using high-performance anion-exchange chromatography with integrated pulsed amperometric detection

Journal of Pharmaceutical and Biomedical Analysis

Volumn 47, Issue 4-5, 2008, Pages 828-833

  Hanko, Valoran P ^a   Rohrer, Jeffrey S ^a   Liu, Harry H ^b   Zheng, Chengmin ^c   Zhang, Shaorong ^c   Liu, Xiaojie ^c   Tang, Xinping ^c  

^a Dionex Corporation1 ^*  (United States)

^b Crick Pharma Inc   (United States)

^c Livzon New North River Pharmaceutical Co Ltd   (China)

Author keywords

2 Deoxystreptamine; Aminoglycoside; Antibiotic; Carbamoyl kanamycin B; Carbamoyl tobramycin; Chromatography; Deoxystreptamine kanosaminide; Electrochemical detection; Fermentation; HPAE IPAD; HPAE PAD; HPLC; Kanamycin A; Kanamycin B; Kanosamine; Neamine; Nebramine; Nebramycin; Neomycin A; Purity; Tobramycin

Indexed keywords

2 DEOXYSTREPTAMINE; AMINE; KANAMYCIN A; KANAMYCIN B; KANOSAMINE; NEAMINE; NEBRAMINE; TOBRAMYCIN;

AMPEROMETRY; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; DRUG DEGRADATION; DRUG IMPURITY; DRUG PURITY; DRUG QUALITY; FERMENTATION; PH; PRIORITY JOURNAL; QUALITY CONTROL; STREPTOMYCES; STREPTOMYCES TENEBRARIUS;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, ION EXCHANGE; DRUG CONTAMINATION; ELECTROCHEMISTRY; FERMENTATION; HYDROGEN-ION CONCENTRATION; KANAMYCIN; NEBRAMYCIN; NEOMYCIN; QUALITY CONTROL; REFERENCE STANDARDS; STREPTOMYCES; TECHNOLOGY, PHARMACEUTICAL; TOBRAMYCIN;

EID: 46549083817     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.04.002     Document Type: Article

References (12)

1. Barnhart E.R. Physicians' Desk Reference PDR, 50th ed. (1996), Medical Economics Company, Inc., Oradell, New Jersey
2. Electronic Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs. Current through April 2007. http://www.fda.gov/cder/ob.
3. European Pharmacopoeia (EP), fifth edition (Version 5.0), Tobramycin. Section 0645. The Council of Europe, 67075 Strasbourg Cedex, France, 2002.
4. Brandl M., and Gu L. Drug Dev. Ind. Pharm. 18 (1992) 1423-1436
5. Koch K.F., Merkel K.E., O'Connor S.C., Occolowitz J.L., Paschal J.W., and Dorman D.E. J. Org. Chem. 43 (1978) 1430-1434
6. Hanko V.P., and Rohrer J.S. J. Pharm. Biomed. Anal. 40 (2006) 1006-1012
7. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Q7, Current Step 4 Version, dated 10 November 2000. http://www.ICH.org.
8. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Impurities In New Drug Substances, Q3A(R2), Current Step 4 Version, dated 25 October 2006. http://www.ICH.org.
9. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Impurities In New Drug Substances, Q3B(R2), Current Step 4 Version, dated 2 June 2006. http://www.ICH.org.
10. Thayer J., Rohrer J.S., Avdalovic N., and Gearing R.P. Anal. Biochem. 256 (1998) 207-216
11. Cheng J., Jandik P., and Avdalovic N. Anal. Chem. 75 (2003) 572-579
12. Stark W.M., Knox N.G., and Wilgus R.M. Folia Microbiol. 16 (1971) 205-217